#United States #NASDAQ #financial results #Amgen #Thousand Oaks

Amgen to Report Third Quarter Financial Results

Amgen, a leading biotechnology company, has announced the date for its much-anticipated third quarter financial results for 2026. The financial report will be made available on November 3, 2026, after the close of U.S. financial markets. Following the release, investors and analysts are welcomed to join a conference call at 4:30 p.m. ET where key insights will be shared by Amgen’s leadership team.

The Call Details

During the conference call, the spotlight will be on Robert A. Bradway, Amgen's Chairman and CEO, along with other senior management team members who will discuss the financial performance and broader business strategies. The call aims to address shareholders directly, offering them an opportunity to increase their understanding of the company’s current standing and direction.

Webcast Accessibility

For those unable to participate in the live call, Amgen will provide a live audio broadcast of the conference through its official website, ensuring that news media, investors, and the public can gain access to this crucial information simultaneously. Furthermore, the webcast will be archived, making it available for replay for at least 90 days post-event, allowing stakeholders and analysts to revisit the discussion at their convenience.

About Amgen

Founded over 45 years ago in Thousand Oaks, California, Amgen specializes in discovering, developing, manufacturing, and delivering innovative medicines aimed at tackling some of the most challenging diseases. The company integrates cutting-edge biotechnology and human genetic insights to develop its diverse and impactful medication portfolio. Amgen has carved a niche in various therapeutic areas including cancer, inflammatory conditions, rare diseases, heart disease, and obesity-related health issues.

Industry Recognition

Amgen has been consistently recognized for its forward-thinking innovations and workplace environments, receiving accolades from Fast Company and Forbes. As a member of the Dow Jones Industrial Average and part of the Nasdaq-100 Index, Amgen stands among the most significant non-financial companies, highlighting its influence and contributions to the biotechnology sector.

Looking Forward

As the date approaches, Amgen maintains its commitment to transparency and strong communication with its stakeholders. Investors and individuals interested in the company’s impact on the healthcare landscape are encouraged to stay tuned for further updates regarding the webcast and subsequent reporting. For more information, interested parties can visit Amgen's official website or follow the company on social media platforms including X, LinkedIn, and Facebook.

In this ever-evolving landscape of biopharmaceuticals, stay informed about Amgen’s advancements and strategies aimed at delivering hope through innovation.

Contact Information

For additional inquiries, Amgen's media contact is Elissa Adair at (609) 251-1407, while Casey Capparelli is available at (805) 447-1746 for investor relations inquiries.